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Abstract. The Mannose 6 Phosphate/Insulin-like Growth Factor Receptor-2 (IGF2R) encodes a type-1 membrane protein that
modulates availability of the potent mitogen, IGF2. We evaluated the associations between IGF2R non-synonymous genetic
variants (c.5002G>A, Gly1619Arg(rs629849), and c.901C>G, Leu252Val(rs8191754)), circulating IGF2 levels, and colon cancer
(CC) risk among African American and White participants enrolled in the North Carolina Colon Cancer Study (NCCCS).
Generalized linear models were used to compare circulating levels of IGF2 among 298 African American and 518 White controls.
Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of
IGF2R genetic variants and CC risk. Women homozygous for the IGF2R c.5002 G>A allele, had higher mean levels of circulating
IGF2, 828 (SD = 321) ng/ml compared to non-carriers, 595 (SD = 217) ng/ml (p-value = 0.01). This pattern was not apparent
in individuals homozygous for the IGF2R c.901 C>G variant. Whites homozygous for the IGF2R c.901 C>G variant trended
towards a higher risk of CC, OR = 2.2 [95% CI(0.9–5.4)], whereas carrying the IGF2R c.5002 G>A variant was not associated
with CC risk. Our findings support the hypothesis that being homozygous for the IGF2R c.5002 G>A modulates IGF2 circulating
levels in a sex-specific manner, and while carrying the IGF2R c.901 C>G may increase cancer risk, the mechanism may not
involve modulation of circulating IGF2.
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1. Introduction
Colon cancer is the third most commonly diagnosed
cancer and the second leading cause of cancer death in
the US [1,2]. Over 106,600 new cases are diagnosed
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each year and 55,170 individuals die from this dis-
ease in the U. S. alone [1]. The highest incidence and
mortality are among African Americans and individu-
als residing in the southeastern seaboard of the United
States [2]. Whereas reasons for higher mortality can
be attributed to poorer access to screening resulting in
later stage at diagnosis amongAfricanAmericans com-
pared to Whites [3], reasons for higher incidence are
unclear. The interaction of genetic and environmental
factors has been hypothesized to underlie racial differ-
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ences for some time [4], however, the causative genet-
ic loci are still unknown. Genetic variation in genes
encoding insulin and insulin-like growth factors (IGF)
have been evaluated in relation to CC risk although
the focus has been on IGF1 [4–10]. Few studies have
evaluated IGF2, also a potent mitogenic growth fac-
tor, in circulation at higher physiologic concentrations
than IGF1; IGF2 also has been associated with several
malignancies [11].
The Mannose 6 Phosphate/Insulin-like Growth Fac-
tor 2 Receptor (IGF2R) encodes a ∼300 kDa multi-
functional type 1 membrane protein recently identified
as a tumor suppressor [12,13]. Although IGF2R reg-
ulates transport of lysosomal proteases and activates
latent transforming growth factor β1, a potent growth
inhibitor [14], this receptor also sequesters free IGF2
ligand, internalizing it for intracellular trafficking to the
lysosomes for degradation [13–18], thereby modulat-
ing IGF2 availability and its mitogenic activity. In the
mouse, loss of IGF2R function results in disproportion-
ate embryonic overgrowth and perinatal death [19,20].
In human cells, loss of IGF2R function has been asso-
ciated with the development of cancers of the breast,
lung, liver and ovary [21,22].
More than 1,700 genetic variants of IGR2Rhave been
reported to the NCBI database to date. In functional
studies, Killian and Jirtle et al. [13] described six of
these SNPs in the coding region of IGF2R, of which
three are non-synonymous [c.6206 A>G, Asn2020Ser;
c.901C>G, Leu252Val and c.5002G>A Gly1619Arg].
The effects of these genetic polymorphism on IGF2R
function are only now beginning to be elucidated in
physiological studies [15,23]. Despite their function-
al significance, these genetic variants are generally
not interrogated in Genome-wide Association Stud-
ies (GWAS), because the commonly used Affymetrix
100K [24] and the Illumina Hap300 [25] chips do not
include these rare alleles. Herein we evaluate two of
the three non-synonymous IGFR2 variants, c.901 C>G
and c.5002 G>A, that have a minor allele population
frequencyof more than 5%, their associationwith high-
er IGF2 circulating levels, and colon cancer risk in
African Americans and Whites.
2. Methods
2.1. Study participants
Study participants were recruited as part of the North
Carolina Colon Cancer Study (NCCCS) and detailed
accrual methods have been described in earlier re-
ports [26]. Briefly, the NCCCS is a population-based,
case-control study based in 33 contiguous rural and ur-
ban counties in central North Carolina comprising 39%
African Americans (294 cases and 437 controls) and
61%Whites (349 of them cases and 611 controls). Cas-
es of histologically confirmed invasive adenocarcino-
ma of the colon aged 40–85 diagnosed between July 1,
1996 and June 30, 2000 were identified using the rapid
case ascertainment system administered by the North
Carolina Cancer Registry. Because the sampling frame
for < 65 year age group was the drivers’ license roster,
cases aged < 65 years had to have a North Carolina’s
driver’s license or state identification cards. To over-
sample African Americans and women, and also main-
tain analytic flexibility, a randomized recruitment strat-
egy [27,28] was employed; adjusted for in statistical
analyses using a sampling fraction determined a priori.
Controls under age 65 were sampled from the North
Carolina’s Division of Motor Vehicles driver’s license
list, matched by race and sex and frequency-matched
by 5-year age group. Controls aged 65 years and older
were frequency-matched to cases using the Medicare-
eligible beneficiaries’ roster. We were able to contact
86% of cases identified through the registry, and (84%),
agreed to participate, an overall response rate of 72%,
higher in Whites (76%) than AfricanAmericans (62%).
Ninety-percent of controls identified were successful-
ly contacted and of these, 62%, agreed to participate.
Individuals who refused to participate or could not be
reached were slightly younger than those who partici-
pated. The study was approved by the IRB at the Uni-
versity ofNorthCarolina and all patients gave informed
consent.
2.2. Data collection
Questionnaire data were collected using a standard-
ized questionnaire by trained interviewers in person
as previously described [26]. Information solicit-
ed included socio-demographic characteristics such as
age, sex, marital status, education and household in-
come; anthropometric measurements, including esti-
matedweight one year prior to the interview and weight
at interview, family history of cancer and personalmed-
ical history, as well as lifestyle factors that included
physical activity, occupational history, smoking habits,
and caloric intake. Weight, circumference of the waist
and hip, and height were also measured at the time
of interview. Information on nutrition was obtained
using a version of the Block semi-quantitative ques-
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tionnaire [29,30] modified to include some regional
foods common in NC with a one year reference to
fully account for seasonality. The questionnaire has
been validated [31]. Information on non-steroidal anti-
inflammatory drugs (NSAID) use was based on an af-
firmative response to a battery of questions about fre-
quency of intake of several pharmaceutical products by
name.
2.3. Collection and processing of blood specimens
Blood samples were collected from consenting par-
ticipants at the time of the interview. All blood speci-
mens were received by the laboratory within 24 hours,
where buffy coat and plasma were separated, aliquot-
ed and stored at −80◦C. Eighty six percent of cases
(n = 529) and 83% of controls (n = 836) who agreed
to participate also agreed to provide peripheral blood
samples for DNA and protein analyses. Participants
who gave bloodwere more likely to be male, white, and
to have never smoked compared to those who did not
donate blood samples. To evaluate whether individu-
als who providedblood samples systematically differed
from those who declined, we compared anthropomet-
ric measurements, NSAID use and stage at diagnosis
of cases and found blood donors and non-donors to be
comparable (data not shown).
2.4. Enzyme linked immunosorbent assays (ELISA)
for IGF2
Plasma IGF2 was measured after acid-ethanol ex-
traction to remove IGFBPs using reagents from Diag-
nostic Systems Laboratory (Webster, Texas), accord-
ing to manufacturer’s protocol. These analyses were
measured in duplicates on stored plasma samples and
laboratory personnel were blinded to the case or con-
trol status of samples. IGF2 levels were measured in
805 and 522 blood samples of the controls and cases,
respectively. Each assay batch included positive con-
trols, and masked samples derived from pooled plasma
specimens labeled in a manner identical to that of study
samples. Assay results were evaluated for implausi-
ble values and samples with questionable values were
repeated. The intra-assay coefficient of variation was
1.5%, and the inter-assay coefficient of variation was
less than 12%.
2.5. Genotyping
Genomic DNA was extracted from buffy coat using
the PureGene DNA isolation kit (Gentra Systems, Inc.,
Minneapolis, MN). Genotyping was done using the 5’
exonuclease (Taqman) assay. Primers for the IGF2R
c.5002 G>A (rs629849) and c.901 C>G (rs8191754)
variants were designed by Applied Biosystems (Foster
City, CA). For c.901 C>G, the forward primer was 5’-
CTA AGG GTA CTG TGA TTA TCA CTC-3’ and the
reverse primerwas 5’-GAAAGT CAG GTC CTT GCT
GGA G-3’. For the c.5002 G>A, the forward primer
was 5’-GAA ATT GAT GGT CCT GAC TTG CG-3’
and the reverse primer was 5’-GCA CTG GAG ATG
CAC TTC TCC-3’. For quality control, a randomly se-
lected 10% of samples were run in duplicate and geno-
typing was conducted without the knowledge of case
status. Undetermined genotypes were excluded from
analyses and constituted 1% and 0.7% of the total pop-
ulation for the IGF2R c.901 C>G and IGF2R c.5002
G>A variants, respectively. The average genotype con-
cordance rate for duplicate samples was > 98%.
2.6. Statistical analyses
We used chi-square tests to evaluate deviation from
Hardy-Weinberg equilibrium (HWE) of IGF2R c.5002
G>A and IGF2R c.901 C>G genotypes among controls
for Whites and African Americas separately. We used
t-tests and analysis of variance, to evaluate mean differ-
ences in IGF2 levels between individuals who carried
one or two of theminor alleles (‘CG’ or ‘GG’ for IGF2R
c.901 C>G; ‘GA’ or ‘AA’ for IGFR2 c.5002 G>A)
and those homozygous for the common allele (‘CC’ or
‘GG’, for IGF2R c.901 C>G and IGF2R c.5002 G>A,
respectively), adjusting for sex, age and race, since par-
ticipants varied by these characteristics. Unconditional
logistic regression models were used to estimate odds
ratios (ORs) and 95% confidence intervals (CIs) for
the association between carrying these genotypes and
risk of colon cancer risk, again comparing carriers of
at least one of the minor alleles to non-carriers, adjust-
ing for potential confounding factors. Matching vari-
ables age, sex and race were included in all models es-
timating main effects as was the sampling fraction [26–
28]. Effect modification by body mass index (BMI =
kg/m2), cigarette smokers (ever, vs. never), caloric in-
take (1,800 ormore vs. less than 1,800 calories per day),
circumference of the waist (< 102 cm vs.  102cm),
use of NSAIDS (NSAID use for  15 months vs. < 15
months in preceding diagnosis for cases and interview
for controls), was evaluated using stratified analyses
and cross-product terms of the genotype and potential
effect modifier. We also assessed potential confound-
ing by socioeconomic factors including household in-
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Table 1
Distribution of characteristics of cases and controls in the North Carolina Colon Cancer Study
White men (n = 466) White women (n = 371) Black men (n = 263) Black women (n = 294)
Characteristic Case Control Case Control Case Control Case Control
Age Group n (%) n (%) n (%) n (%) n (%) n (%) n(%) n (%)
< 65 75 (44) 111 (37) 56 (41) 81 (35) 64 (55) 65 (45) 67 (55) 62 (36)
 65 94 (56) 186 (63) 81 (59) 153 (65) 53 (45) 81 (55) 55 (45) 110(64)
Education Level
< HS grad 50 (30) 67 (23) 32 (23) 46 (20) 58 (50) 59 (40) 49 (40) 74 (43)
HS grad, college 74 (44) 137 (46) 79 (58) 136 (52) 50 (43) 70 (48) 64 (53) 78 (45)
College grad or more 44 (26) 92 (31) 26 (19) 52 (22) 9 (8) 17 (12) 8 (7) 20 (12)
NSAID use in past year
Yes 81 (48) 175 (59) 48 (35) 122 (52) 46 (39) 67 (46) 35 (29) 92 (53)
No 88 (52) 122 (41) 89 (65) 112 (48) 71 (61) 79 (54) 86 (71) 80 (47)
BMI 1 year ago
18.5–25 (Normal) 29 (17) 76 (26) 54 (41) 80 (36) 25 (22) 31 (23) 9 (8) 28 (18)
25–30 (Overweight) 79 (48) 143 (49) 46 (35) 77 (34) 49 (42) 63 (46) 47 (42) 48 (30)
30+ (Obese) 58 (35) 70 (24) 31 (24) 68 (30) 42 (36) 43 (31) 56 (50) 84 (52)
Regular Multivitamin User
Yes 64 (39) 141 (51) 74 (56) 136 (61) 36 (32) 43 (31) 37 (32) 73 (45)
No 100 (61) 134 (49) 59 (44) 86 (39) 78 (68) 98 (69) 77 (68) 90 (55)
Smoking Status
Current 21 (13) 55 (19) 20 (15) 28 (12) 30 (26) 42 (29) 20 (17) 30 (17)
Former 111 (66) 158 (53) 50 (36) 81 (35) 51 (44) 62 (42) 30 (25) 46 (27)
Never 35 (21) 83 (28) 67 (49) 125 (53) 35 (30) 42 (29) 70 (58) 96 (56)
Alcohol Use
Yes 74 (45) 138 (48) 47 (35) 70 (31) 38 (33) 39 (27) 12 (10) 19 (11)
No 90 (55) 148 (52) 88 (65) 157 (69) 77 (67) 105 (73) 104 (90) 147 (89)
Calories per day
 1,800 44 (27) 102 (35) 88 (64) 175 (75) 40 (37) 71 (50) 72 (62) 123(74)
> 1,800 120 (73) 192 (65) 49 (36) 58 (25) 68 (63) 70 (50) 44 (38) 43 (26)
come and education, as well as lifestyle factors, in-
cluding daily average caloric intake, cigarette smoking
and frequency of alcohol intake. These factors did not
change the β-coefficient for the association between
genotypes evaluated and colon cancer by  10%, and
were thus not retained in final models. Statistical mod-
els were developed for African Americans and Whites
separately and then combined. We used SAS version
9.1 (SAS, Cary, NC, USA) for all statistical analyses.
3. Results
Characteristics of study participants have been pre-
viously described in several reports [26,32,33]. Table 1
summarizes the distribution of characteristics of study
participants. Although minor gender variations were
noted, in general, when compared to controls, cases
were older, reportedhigher daily average caloric intake,
had a higher BMI one year prior to interview, a larger
waist circumference at interview, and were less likely
to report intake of NSAIDs. However, cases did not
significantly differ from controls with respect to edu-
cation, alcohol consumption and a history of cigarette
smoking.
To gain insights into the functional significance of
IGF2R genetic variants, we evaluated whether individ-
uals who carry the IGF2R c.5002 G>A and IGF2R
c.901 C>G variants had higher average circulating lev-
els of the IGF2 ligand among otherwise healthy con-
trols (Table 2). We found that individuals homozygous
for the IGF2R c.5002 G>A variant had higher mean
levels of circulating IGF2, 593 (SD = 204) ng/ml com-
pared to non-carriers, 563 (SD = 206) ng/ml (p-value
= 0.06). These differences in mean IGF2 levels were
most pronounced among women (p-value= 0.01). No-
tably, a gene-dose response trend was apparent in both
African Americans and Whites (p for trend = 0.003).
Adjusting for age, sex and race did not alter these find-
ings.
We also found that individuals carrying at least one
IGF2R c.901 C>G allele had higher mean circulating
IGF2 levels, 587 (SD = 205) ng/ml) when compared
to individuals who did not carry the genetic variant,
563 (SD = 205) ng/ml (p-value = 0.15). However,
mean IGF2 concentrations were higher in individuals
heterozygous for the IGF2R c.901 C>G allele, 592 (SD
= 208) ng/ml) than those homozygous for this allele
520 (SD = 146) ng/ml (p-value = 0.09). These anal-
yses were repeated in Whites and African Americans
C. Hoyo et al. / IGF2R gene variants and colon cancer 137
Table 2
Means and standard deviations of plasma IGF2 levels (ng/ml) in n = 805 controls carrying the IGF2R
c.901 and C.5002 variants
Characteristic IGF2R c.901C>G, IGF2R c.5002G>A,
rs8191754 rs629849
Variant Mean (sd) p-value Variant Mean (sd) p-value
All1
CC (n = 610) 563 (205) GG (n = 661) 563 (206)
CG (n = 182) 592 (208) 0.09 AG (n = 129) 586 (193) 0.25
GG (n = 13) 520 (146) 0.46 AA (n = 10) 684 (313) 0.06
CG and GG (n = 195) 587 (205) 0.15 AG and AA (n = 139) 593 (204) 0.12
Men2
CC (n = 314) 537 (192) GG (n = 336) 532 (188)
CG (n = 102) 552 (173) 0.48 AG (n = 84) 573 (180) 0.07
GG (n = 9) 521 (162) 0.92 AA (n = 4) 469 (139) 0.50
CG and GG (n = 111) 551 (171) 0.52 AG and AA (n = 88) 569 (179) 0.10
Women2
CC (n = 296) 590 (214) GG (n = 325) 595 (217)
CG (n = 80) 642 (237) 0.06 AG (n = 45) 608 (215) 0.71
GG (n = 4) 496 (117) 0.39 AA (n = 6) 828 (321) 0.01
CG and GG (n = 84) 635 (235) 0.09 AG and AA (n = 51) 634 (237) 0.24
White3
CC (n = 381) 587 (216) GG (n = 387) 589 (219)
CG (n = 119) 618 (218) 0.18 AG (n = 111) 595 (199) 0.80
GG (n = 9) 515 (166) 0.32 AA (n = 8) 687 (352) 0.21
CG and GG (n = 128) 611 (216) 0.29 AG and AA (n = 119) 602 (212) 0.59
Afr. American3
CC (n = 229) 522 (177) GG (n = 274) 526 (179)
CG (n = 63) 542 (180) 0.42 AG (n = 18) 525 (139) 0.98
GG (n = 4) 533 (106) 0.90 AA (n = 2) 672 (115) 0.24
CG and GG (n = 67) 542 (176) 0.42 AG and AA (n = 20) 540 (141) 0.74
1Adjusted for age, sex and race; 2Ajusted for age and race; 3Ajusted for age and sex.
Table 3
Adjusted1 odds ratios and 95% CIs for the association between carrying the IGF2R c.901 and c.5002 variants in African Americans and Whites
IGF2R c.901C >G, rs8191754 IGF2R c.5002G >A, rs629849
Genotype Cases Controls OR (95% CI), p-value Genotype Cases Controls OR (95% CI), p-value
All n (%) n (%) n (%) n (%)
CC 400 (74) 640 (76) GG 457 (85) 691 (83)
CG 123 (23) 187 (22) 1.1 (0.8, 1.4), (p = 0.61) AG 79 (15) 133 (16) 1.0 (0.7, 1.3), (p = 0.80)
GG 14 (3) 13 (2) 1.9 (0.9, 4.1), (p = 0.10) AA 3 (0.6) 11 (1) 0.5 (0.1, 1.8), (p = 0.27)
CG and GG 137 (26) 200 (24) 1.1 (0.9, 1.4), (p = 0.37) AG and AA 82 (15) 144 (17) 0.9 (0.7, 1.3), (p = 0.62)
White2
CC 226 (75) 393 (75) GG 238 (78) 397 (76)
CG 66 (22) 121 (23) 1.0 (0.7, 1.3), (p = 0.80) AG 64 (21) 114 (22) 1.0 (0.7, 1.4), (p = 0.79)
GG 11 (4) 9 (2) 2.2 (0.9, 5.4), (p = 0.09) AA 3 (1) 9 (2) 0.6 (0.2, 2.3), (p = 0.47)
CG and GG 77 (26) 130 (25) 1.0 (0.7, 1.4), (p = 0.81) AG and AA 67 (22) 123 (24) 0.9 (0.7, 1.3), (p = 0.67)
African American2
CC 174 (74) 247 (78) GG 219 (94) 294 (93)
CG 57 (24) 66 (21) 1.3 (0.8, 1.9), (p = 0.27) AG 15 (6) 19 (6) 1.0 (0.5, 2.0), (p = 0.91)
GG 3 (1) 4 (1) 1.4 (0.3, 6.6), (p = 0.64) AA 0 (0) 2 (1) − (p = 0.98)
CG and GG 60 (25) 70 (22) 1.3 (0.9, 1.9), (p = 0.24) AG and AA 15 (6) 21 (7) 0.9 (0.4, 1.8), (p = 0.70)
1Adjusted for age, sex and race; 2Adjusted for age and sex.
separately and also in men and women. The patterns
persisted although the difference was most pronounced
in women (p-value = 0.06). We found no evidence
for higher IGF2 levels in individuals who carry both
IGF2R c.901 C>G and the IGF2R c.5002 G>A genetic
variants.
Table 3 shows the distribution of genetic variants
IGF2R c.901 C>G and IGF2R c.5002 G>A, and the
ORs and 95% CIs for the associations between carrying
the variant alleles and risk of colon cancer among all
participants and separately by race/ethnicity. Therewas
no evidence that genotype frequencies in the IGF2R
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c.901 C>G deviated from Hardy-Weinberg Equilibri-
um (HWE) among white or African American controls.
Genotype frequencies among controls for the IGF2R
c.901 CG and GG were 21% and 1% respectively in
African Americans, and 23% and 2% respectively in
Whites. Control participants genotype frequencies for
the IGF2R c.5002 AG and AA were 22% and 2% re-
spectively in Whites, and 6% and 1% in African Amer-
icans. While IGF2R c.5002 G>A genotype frequen-
cies for White controls did not deviate from HWE (p-
value>0.49), African American women controls devi-
ate from HWE (p-value = 0.02). These frequencies
are consistent with those reported in public databases,
HapMap and NCBI databases.
A trend towards a significant association between
homozygous for the G-allele for the IGF2R c.901C>G
and colon cancer risk in all participants, OR = 1.9
[95% CI(0.9–4.1)] was observed. This association ap-
peared to be primarily among Whites, OR = 2.2 [95%
CI(0.9–5.4)] and not African Americans, OR = 1.4
[95% CI(0.3–6.6)]. However, the number of individu-
als homozygous for this genotype inAfricanAmericans
was small. This association did not vary by NSAID
use, BMI, waist circumference, cigarette smoking and
daily caloric intake, (data not shown). We found no
evidence for an association between being homozy-
gous for the IGF2R c.5002 G>A and colon cancer
risk among Whites, OR = 0.9 [95% CI(0.7–1.3)], and
African Americans, OR = 0.9 [95% CI(0.4–1.8)]. We
also evaluated whether the accumulation of the two ge-
netic variants increased colon cancer risk, and no such
synergistic association was found, (data not shown).
4. Discussion
We present the first population-based, epidemiologic
evidence that otherwise healthy individuals who carry
the non-synonymous IGF2R c.901 C>G, Leu252Val or
c.5002 G>A Gly1619Arg genetic variants have high-
er average IGF2 levels. Gene-dose response trends
were most apparent in individuals homozygous for the
IGF2R c.5002 G>A. We also observed a trend to-
wards an increased risk of colon cancer in white IGF2R
c.901 C>G carriers. The accumulation of the two at-
risk genotypes did not alter the association of these
genotypes with protein levels, nor with colon cancer
risk. Despite the identification of the IGF2 chromoso-
mal location as one of three colon cancer susceptibil-
ity loci [34,35], the non-synonymous IGF2R genetic
variants evaluated here have not been interrogated in
Genome-wide Association Studies (GWAS), because
the commonly used Affymetrix 100K [24] and the Il-
lumina Hap300 [25] chips do not include these genetic
variants.
Our findings that carrying the IGF2R c.5002 G>A is
associatedwith elevated IGF2 levels are consistentwith
previous studies showing that variant IGF2R c.5002
G>A disrupts IGF2 ligand binding functions within
IGF2R domain 11 [36,37]. However, a more recent
NMR study showed no association between this poly-
morphism and IGF2 binding [15], and crystallography
data showed that Gly1619Arg does not lie within the
IGF2 binding site [16]. This polymorphism though,
could be affecting splice site choice and exon skipping
either directly or through linkage disequilibrium (LD)
with other SNPs located in intronic sequences [15]. A
recent study found a threefold increased risk of ad-
vanced oral squamous cell carcinoma in individuals car-
rying the IGF2R c.5002 variant Gly1619Arg A-allele
compared to the wild type or G-allele [38]. IGF2R
variant haplotypes were also associated with increased
pancreatic cancer risk [39]. IGF2 circulating levels
were not reported in these studies. Zhao et al. [40],
reported that very high levels of circulating IGF2 are
found in advanced colorectal cancer, however Renehan
et al. [41] found an association between serum IGF2
and early colon cancer stages.
IGF2R binds and internalizes IGF2 maintaining ap-
propriate levels of IGF2 locally and in circulation.
When this equilibrium is disrupted either by loss of
IGF2R function [18–20]or IGF2 loss of imprinting [42,
43], increased growth occurs in human and murine tu-
mors [44,45]. However, the exact mechanism and its
association to IGF2R polymorphisms is still unknown.
Evidence based on published data suggests that even
if IGF2R c.5002 G>A has no effect on function, it is
in strong LD with a causative mutation. However, in-
formatics suggest that IGF2R c.5002 G>A may have a
regulatory effect at the RNA level. IGF2R c.5002 G>A
sits in possible binding sites for multiple miRNAs, with
the G and A alleles creating sequences complementary
to different miRNAs. In addition, splice site predic-
tions shows that the A- allele may create a splice accep-
tor site, as well as eliminate an enhancer motif for Ser-
ine/Arginine (SR) protein binding [46]. Recent results
have indicated that IGF2R exon 34, which contains
c.5002 G>A, is affected by alternative splicing, and
is also contained in an antisense transcript [47]. The
role of IGF2R c.5002 G>A or linked polymorphisms
in splice site choice, as well as antisense expression or
function, have yet to be determined.
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We observed a different population distribution for
the IGF2R c.5002 G>A variant when we stratified by
sex and race; HWE deviations were more common in
women (p = 0.003) and in African Americans (p =
0.02). HWE deviations in black women could have
been due, at least in part to small sample size of African
Americans (n = 20) carrying the IGF2R c.5002 G>A
allele, compared to Whites (n = 119); genotyping er-
rors were uncommon. Furthermore, IGF2R c.5002
G>A is a rare allele in linkage disequilibrium (LD)with
a potentially functional mutation. The level of LD is
influenced by the rate of mutation and population struc-
ture and it is known to influence HWE [48]. However,
the association of variant IGF2R c.5002G>A and IGF2
levels in women is strong (p = 0.01) and unlikely to be
affected by the deviation from HWE, although further
studies with a larger sample of women are required.
Although we also found a correlation between high-
er levels of IGF2 and carriers of the IGF2R c.901 C>G
variant in healthy women, the molecular mechanisms
underlying the suggested association are unclear and
may differ from those related to the IGF2R c.5002G>A
variant. The amino acid variant c.901 Leu252Val is
located in repeat domain 3 and this domain is involved
in binding M6P moieties on other proteins [12]. Thus,
IGF2R c.901 C>G may also alter function by changing
the affinity for M6P bearing ligands which in turn may
alter protein trafficking, with a consequent increase in
the IGF2 ligand [50,51]. In predominantly white pop-
ulations, carrying the IGF2R c.901 C>G has been as-
sociated with another gastrointestinal malignancy [52]
and a tall stature [53]. Tall stature has been associat-
ed with colon cancer risk [54], and elevated IGF2 lev-
els [55]. In the current data set, colon cancer risk was
of borderline significance in Whites homozygous for
the c.901 GG variant, and intriguingly, four of the five
women were colon cancer cases compared to seven of
fifteen men.
Data from publically available databases including
HapMap and SNP500, suggest that the relative pop-
ulation frequency of IGF2R c.901 C>G and IGF2R
c.5002 G>A do not parallel the higher incidence of
colon cancer in African Americans. The prevalence
of IGF2R c.901 C>G is similar in Whites (25%) and
African Americans (22%), yet the risk of colon can-
cer associated with carrying this allele differs markedly
between the two groups. In contrast, IGF2R c.5002
G>A is rare in African Americans (13%) and common
in Whites (36%). This may suggest that while these
genetic variants may contribute to modulating IGF2
concentrations via IGF2R binding, other mechanisms
including deregulation of genomic imprinting may also
play a role. Relaxation of imprinting controls leading
to biallelic expression of IGF2 may also increase cir-
culating IGF2 ligand directly and this may be impor-
tant since the population frequency of IGF2 loss of im-
printing could be as high as 10% to 20% in the popula-
tion [51]. IGF2 loss of imprinting has been associated
with a five-fold increase in colon cancer risk [34,35].
When taken together, IGF2R c.5002 G>A and c.901
C>G polymorphisms may exert their effects in a mul-
tifaceted manner, among them, by modulating IGF2 in
circulation.
A major strength of this study is that it is one of
the largest population-based case-control studies with
the largest number of African Americans included, en-
abling evaluation of genetic effects on both colon can-
cer risk and on IGF2 protein concentrations in African
Americans and Whites. Although this is not a genome-
wide study and we cannot exclude the influence of oth-
er genes or other genetic variants in the insulin growth
factor or related pathways, we evaluated genetic vari-
ants known to be amino acid-changing and found pos-
itive associations between carrying either variant and
IGF2 protein levels. Despite its size, a limitation of
this study is that the sample size limited our ability to
adequately evaluate race-specific associations of these
relatively rare alleles, as well as gene-environment in-
teraction effects on colon cancer risk within race/ethnic
group-specific associations. Departure fromHWE may
have been due, at least in part, to small sample size and
rare allele frequencies of variant IGF2R c.5002 G>A
in African American women.
In summary, we provide the first epidemiologic evi-
dence that women homozygous for the IGF2R c.5002
G>A genetic variant have, on average, higher circulat-
ing levels of the mitogen IGF2. IGF2 is associated with
increased risk of developing colorectal neoplasia. Our
data also suggest that carrying the non-synonymous
IGF2R c.901 C>G may be associated with increased
colon cancer risk, although this association may not
be via modulation of the ligand. Future studies in a
larger sample of individuals carrying these rare allele
variants are required to evaluate IGF2 levels and CC
risk associations.
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